Group Purchasing Organization (GPO)

Key facts

Anti-Kickback protection

Statutory exception and safe harbor at 42 CFR 1001.952(j)

Vendor fee condition

Written agreement stating fees of 3 percent or less, or the amount

Funding

Typically administrative fees paid by vendors

Members

Hospitals, health systems, physician practices, long-term care and pharmacies

What is a group purchasing organization?

Hospitals and health systems buy thousands of products, from syringes and implants to injectable drugs. A GPO aggregates demand from many members, negotiates contract prices and terms with suppliers, and makes those contracts available to members, who then buy through distributors or directly from manufacturers.

GPOs usually do not take ownership of products. Contract prices are typically implemented through distributors, which sell at the GPO price and recover the difference from the manufacturer through chargebacks.

Most GPOs are funded by administrative fees that vendors pay based on members' purchases, and some share part of those fees with members. That model is protected under a specific exception to the federal Anti-Kickback Statute when written agreement and disclosure conditions are met.

Types of GPOs in drug purchasing

GPOs are often organized around the members they serve:

• Hospital GPOs: negotiate for acute care hospitals and health systems across drugs, devices and supplies.
• Specialty and physician practice GPOs: common in oncology, rheumatology and other buy-and-bill specialties.
• Pharmacy GPOs: help independent retail pharmacies buy generics and other drugs.
• Alternate site GPOs: serve long-term care, home infusion, surgery centers and clinics.

Why GPOs matter

For manufacturers, GPO contracts are a main route into hospital and clinic purchasing, and GPO prices flow into government price calculations such as Average Sales Price and, when low enough, Medicaid Best Price.

340B rules add a constraint: disproportionate share hospitals, children's hospitals and freestanding cancer hospitals generally cannot buy covered outpatient drugs through a GPO, so they keep separate 340B and non-GPO purchasing accounts. HRSA's 340B Prime Vendor Program negotiates sub-ceiling prices for covered entities.

Critics argue that vendor-paid fees and sole-source contracts can reduce competition and contribute to shortages of low-margin generic injectables, while GPOs argue they lower costs for providers. Researchers and policymakers continue to debate the evidence.